000163659 001__ 163659
000163659 005__ 20240229133510.0
000163659 0247_ $$2doi$$a10.1007/s00066-020-01684-y
000163659 0247_ $$2pmid$$apmid:32970162
000163659 0247_ $$2ISSN$$a0039-2073
000163659 0247_ $$2ISSN$$a0179-7158
000163659 0247_ $$2ISSN$$a1439-099X
000163659 037__ $$aDKFZ-2020-01936
000163659 041__ $$aeng
000163659 082__ $$a610
000163659 1001_ $$0P:(DE-He78)8bff76ab3cfe753721744ece2dfa32e5$$aEbert, Nadja$$b0$$eFirst author$$udkfz
000163659 245__ $$aResults of a randomized controlled phase III trial: efficacy of polyphenol-containing cystus® tea mouthwash solution for the reduction of mucositis in head and neck cancer patients undergoing external beam radiotherapy.
000163659 260__ $$aHeidelberg$$bSpringer Medizin$$c2021
000163659 3367_ $$2DRIVER$$aarticle
000163659 3367_ $$2DataCite$$aOutput Types/Journal article
000163659 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1679390929_27551
000163659 3367_ $$2BibTeX$$aARTICLE
000163659 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163659 3367_ $$00$$2EndNote$$aJournal Article
000163659 500__ $$a#EA:E220#LA:E220#2021 Jan;197(1):63-73
000163659 520__ $$aTo determine the effect of Cystus® tea (Naturprodukte Dr. Pandalis GmbH & Co. KG) as mouthwash compared to sage tea on oral mucositis in patients undergoing radio(chemo)therapy for head and neck cancer.In this randomized, prospective phase III study, 60 head and neck cancer patients with primary or postoperative radio(chemo)therapy were included between 04/2012 and 06/2014. They received either sage or Cystus® tea for daily mouthwash under therapy. Mucositis was scored twice a week following the Radiation Therapy Oncology Group and the European Organization for Research and Treatment Cancer (RTOG/EORTC) scoring system. Dental parameters were also recorded. Statistical evaluation of the primary endpoint was performed using t‑test and log rank test.Data from 57 patients could be evaluated. Patient characteristics showed no significant difference between the two groups (n = 27 sage; n = 30 Cystus®). A total of 55 patients received the prescribed dose (60-66 Gy postoperative; 70-76.8 Gy primary). Mucositis grade 3 was observed in 23 patients (n = 11 sage; n = 12 Cystus®) and occurred between day 16 and 50 after start of therapy. There was no significant difference between the two groups in latency (p = 0.75) and frequency (p = 0.85) of the occurrence of mucositis grade 3. The self-assessment of the oral mucosa and the tolerability of the tea also showed no significant differences. Occurrence of dental pathologies appeared to increase over time after radiotherapy.Cystus® and sage tea have a similar effect on the occurrence of radiation-induced mucositis regarding latency and incidence. Cystus® tea mouthwash solution is tolerated well and can be applied in addition to intensive oral care and hygiene along with the application of fluorides.
000163659 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000163659 588__ $$aDataset connected to CrossRef, PubMed,
000163659 7001_ $$0P:(DE-HGF)0$$aKensche, Anna$$b1
000163659 7001_ $$0P:(DE-HGF)0$$aLöck, Steffen$$b2
000163659 7001_ $$0P:(DE-He78)f3a873e7ab94ef36c11fcf1023c8d860$$aHadiwikarta, Wahyu Wijaya$$b3$$udkfz
000163659 7001_ $$0P:(DE-HGF)0$$aHänsch, Anna$$b4
000163659 7001_ $$0P:(DE-HGF)0$$aDörr, Wolfgang$$b5
000163659 7001_ $$0P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9$$aKrause, Mechthild$$b6$$udkfz
000163659 7001_ $$0P:(DE-HGF)0$$aHannig, Christian$$b7
000163659 7001_ $$0P:(DE-He78)933f7d725ac87378f459623783585a1f$$aBaumann, Michael$$b8$$eLast author$$udkfz
000163659 773__ $$0PERI:(DE-600)2003907-4$$a10.1007/s00066-020-01684-y$$n1$$p63-73$$tStrahlentherapie und Onkologie$$v197$$x1439-099X$$y2021
000163659 909CO $$ooai:inrepo02.dkfz.de:163659$$pVDB
000163659 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8bff76ab3cfe753721744ece2dfa32e5$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000163659 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000163659 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000163659 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f3a873e7ab94ef36c11fcf1023c8d860$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000163659 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000163659 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000163659 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4be9ccb23f3e472b97743845cd2b3fe9$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000163659 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000163659 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)933f7d725ac87378f459623783585a1f$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000163659 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000163659 9130_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000163659 9141_ $$y2021
000163659 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-01-14$$wger
000163659 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2020-01-14$$wger
000163659 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-14
000163659 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-14
000163659 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-14
000163659 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-14
000163659 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-14
000163659 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-01-14
000163659 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-14
000163659 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-14
000163659 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-14
000163659 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-14
000163659 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-14
000163659 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTRAHLENTHER ONKOL : 2018$$d2020-01-14
000163659 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-14
000163659 9202_ $$0I:(DE-He78)E220-20160331$$kE220$$lE220 Radioonkologie Radiobiologie$$x0
000163659 9201_ $$0I:(DE-He78)DD01-20160331$$kDD01$$lDKTK DD zentral$$x0
000163659 9201_ $$0I:(DE-He78)E220-20160331$$kE220$$lE220 Radioonkologie Radiobiologie$$x1
000163659 9201_ $$0I:(DE-He78)M010-20160331$$kM010$$lM010 Stiftungsvorstand$$x2
000163659 9200_ $$0I:(DE-He78)E220-20160331$$kE220$$lE220 Radioonkologie Radiobiologie$$x0
000163659 980__ $$ajournal
000163659 980__ $$aVDB
000163659 980__ $$aI:(DE-He78)DD01-20160331
000163659 980__ $$aI:(DE-He78)E220-20160331
000163659 980__ $$aI:(DE-He78)M010-20160331
000163659 980__ $$aUNRESTRICTED